Postoperative nausea and vomiting
Drug research and approvals for postoperative nausea and vomiting: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 51 studies of postoperative nausea and vomiting are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 51
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy AdultsNCT07868861 · Phase 1 · Nasus Pharma · starts Sep 15, 2026
- Opioid-Free Anesthesia in FESS: A Prospective ERAS StudyNCT07812389 · Not reported · Filiz Kaya · starts Aug 15, 2026
- Postoperative Nausea, Vomiting and Pain After Bariatric Surgery - a National Registry StudyNCT07797374 · Not reported · Umeå University · starts Oct 1, 2025
- Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to…NCT07777276 · Phase 4 · Telethon Kids Institute · starts Aug 3, 2026
- A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative…NCT07709897 · Phase 2 · Fujian Shengdi Pharmaceutical Co., Ltd. · starts Aug 6, 2026
- Association Between Pain Catastrophizing and PONV in Laparoscopic Cholecystectomy PatientsNCT07712211 · Not reported · Trabzon Kanuni Education and Research Hospital · starts Jan 15, 2026
- Effect of Lidocaine Through Gastric Tube on PONVNCT07643298 · Not applicable · General Hospital of Ningxia Medical University · starts May 20, 2026
- Time to First Rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV…NCT07638527 · Phase 4 · Faisalabad Medical University · starts Sep 1, 2026
- The Use of a Comfort Tote to Improve Recovery in Pediatric and Adolescent Patients After SurgeryNCT07632833 · Not applicable · Columbia University · starts Dec 1, 2026
Approved 21
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
- AprepitantNeurokinin 1 receptor antagonist
- AmisulprideSerotonin (5-HT) receptor antagonist
- PalonosetronSerotonin 3a (5-HT3a) receptor antagonist
- GranisetronSerotonin 3a (5-HT3a) receptor antagonist
- ProchlorperazineDopamine D2 receptor antagonist
- FosaprepitantNeurokinin 1 receptor antagonist
- DroperidolSerotonin 2a (5-HT2a) receptor antagonist
- MetoclopramideDopamine D2 receptor antagonist
- ScopolamineMuscarinic acetylcholine receptor M1 antagonist
- DolasetronSerotonin 3a (5-HT3a) receptor antagonist
- NabiloneCannabinoid CB1 receptor agonist
- RolapitantNeurokinin 1 receptor antagonist
- PyridoxineSupplement
- PerphenazineDopamine D2 receptor antagonist
- PromethazineHistamine H1 receptor antagonist
- ChlorpromazineSerotonin 2a (5-HT2a) receptor antagonist
- MeclizineHistamine H1 receptor antagonist
- DiphenhydramineHistamine H1 receptor antagonist
- Trimethobenzamide
- NetupitantNeurokinin 1 receptor antagonist
Phase 3 12 of 19
- DexamethasoneGlucocorticoid receptor agonist
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- CasopitantNeurokinin 1 receptor antagonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- GabapentinVoltage-gated calcium channel modulator
- RamosetronSerotonin 3 (5-HT3) receptor antagonist
- AcetaminophenCyclooxygenase inhibitor
- BupivacaineSodium channel protein type IV alpha subunit blocker
- CisplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- KetoprofenCyclooxygenase inhibitor
- DoxylamineHistamine H1 receptor antagonist
Phase 2 9
- VestipitantNeurokinin 1 receptor antagonist
- DimenhydrinateHistamine H1 receptor antagonist
- BuspironeSerotonin 1a (5-HT1a) receptor partial agonist
- NicotineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- DiltiazemVoltage-gated L-type calcium channel blocker
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- RopivacaineSodium channel alpha subunit blocker
- Fospropofol
- Ginger
Phase 1 or earlier 4
- GlycopyrroniumMuscarinic acetylcholine receptor M3 antagonist
- Anisodamine
- MirtazapineSerotonin 2a (5-HT2a) receptor antagonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
How its trials ended
517 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 82 whose ending is known, 46% met their primary endpoint, 15% missed it and 39% stopped early.
- Completed, result not reported27353%
- Status unknown8516%
- Ongoing7715%
- Met its primary endpoint387%
- Stopped: other or unclear214%
- Missed its primary endpoint122%
- Stopped: enrollment or feasibility71%
- Stopped: lack of efficacy2<1%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 11, 2003 | EmendAprepitant | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA